Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: A real-world study.

Olga MontvidaJonathan Edward Shaw Lawrence Blonde Sanjoy K Paul

Published in: Diabetes, obesity & metabolism (2018)

Patients treated with second-line incretins and TZDs had a significantly higher probability of achieving and sustaining glycaemic control over 2 years without further intensification, compared with those treated with SUs or insulin.

Keyphrases

type diabetes
glycemic control
metabolic syndrome
skeletal muscle
newly diagnosed